Breakthrough Study Reveals GPER1 Protein's Role in Treating Psoriasis

A new study has highlighted the potential of a protein called GPER1 in treating chronic skin conditions like psoriasis. This receptor, linked to estrogen signalling, appears to slow the overgrowth of skin cells—a key factor in inflammatory skin diseases. Researchers suggest it could pave the way for more targeted therapies with fewer side effects.

The study focused on GPER1, a G protein-coupled receptor that inhibits keratinocyte proliferation—the rapid growth of skin cells often seen in psoriasis. When activated, GPER1 significantly reduces cell division, particularly during the G1 phase of the cell cycle. It also interferes with the MAPK/ERK pathway, lowering levels of inflammatory markers such as TNF-α and IL-6.

In animal tests, mice with induced psoriasis-like inflammation were treated with a GPER1 agonist called G-1. Topical application led to noticeable improvements, including reduced skin thickness, scaling, redness, and lower levels of key inflammatory cytokines like IL-17 and IL-23. These findings suggest that GPER1 agonists could offer a more selective treatment option compared to existing therapies.

Unlike traditional estrogen receptors, GPER1 provides rapid cellular responses, making it a promising target for both topical and systemic treatments. The study also noted that measuring GPER1 levels in patients might help tailor treatments more effectively, supporting a shift toward personalised medicine.

The research underscores GPER1's role in skin health and its potential as a therapeutic target. By reducing inflammation and cell overgrowth, GPER1-based treatments could improve outcomes for patients with chronic skin diseases. Further development of GPER1 agonists may lead to safer, more effective alternatives to current therapies.